Joachim Burman Selected Research

Vertigo (Positional Vertigo)

2/2021	Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension.
11/2018	Intrathecal treatment trial of rituximab in progressive MS: An open-label phase 1b study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joachim Burman Research Topics

Disease

22	Multiple Sclerosis 04/2022 - 06/2012
8	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 02/2015
7	Relapsing-Remitting Multiple Sclerosis 01/2022 - 10/2013
5	Infections 01/2022 - 11/2018
5	Inflammation (Inflammations) 06/2021 - 06/2012
4	Disease Progression 02/2021 - 01/2018
3	Chronic Progressive Multiple Sclerosis 01/2019 - 03/2016
2	COVID-19 01/2022 - 01/2021
2	Nausea 02/2021 - 11/2018
2	Vertigo (Positional Vertigo) 02/2021 - 11/2018
2	Huntington Disease (Huntington's Disease) 01/2021 - 11/2019
2	Cytopenia 01/2021 - 01/2020
1	Bacterial Meningitis 02/2021
1	Thyroid Diseases (Thyroid Disease) 01/2021
1	Epilepsy (Aura) 01/2021
1	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2021
1	Virus Diseases (Viral Diseases) 01/2021
1	Neoplasms (Cancer) 01/2020
1	Atrophy 01/2019
1	Systemic Scleroderma (Systemic Sclerosis) 12/2017
1	Crohn Disease (Crohn's Disease) 12/2017
1	Torticollis (Wryneck) 09/2015
1	Neuromyelitis Optica (Devic's Disease) 02/2015
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 05/2012
1	Encephalomyelitis (Myeloencephalitis) 05/2012

Drug/Important Bio-Agent (IBA)

6	Rituximab (Mabthera)FDA Link 01/2022 - 11/2018
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 03/2016
4	Proteins (Proteins, Gene)FDA Link 06/2021 - 01/2018
3	Alemtuzumab (Campath)FDA Link 01/2021 - 01/2021
3	Natalizumab (Tysabri)FDA Link 01/2020 - 01/2017
2	Glatiramer Acetate (Copaxone)FDA Link 01/2022 - 01/2020
2	Dimethyl FumarateIBA 01/2022 - 10/2020
2	Fingolimod Hydrochloride (FTY720)FDA Link 01/2020 - 01/2020
1	Biological ProductsIBA 04/2022
1	Monoclonal AntibodiesIBA 01/2022
1	BNT162 VaccineIBA 01/2022
1	VaccinesIBA 01/2022
1	InterferonsIBA 01/2022
1	Lamotrigine (Lamictal)FDA LinkGeneric 01/2021
1	proenkephalinIBA 01/2021
1	Immunoglobulins (Immunoglobulin)IBA 10/2020
1	Dihydrotachysterol (AT 10)IBA 01/2020
1	Interferon-betaIBA 01/2020
1	Phenylalanine (L-Phenylalanine)FDA Link 11/2019
1	Tyrosine (L-Tyrosine)FDA Link 11/2019
1	pyrimidineIBA 01/2019
1	Pharmaceutical PreparationsIBA 01/2017
1	nitazoxanide (NTZ)FDA Link 01/2017
1	Botulinum Toxins (Botulinum Toxin)IBA 09/2015
1	abobotulinumtoxinA FDA Link 09/2015
1	Type A Botulinum Toxins (Botox)FDA Link 09/2015
1	Aquaporin 4IBA 02/2015
1	AntibodiesIBA 02/2015
1	CytokinesIBA 12/2014
1	Interleukin-12 (IL 12)IBA 05/2012

Therapy/Procedure

10	Therapeutics 01/2022 - 05/2012
10	Hematopoietic Stem Cell Transplantation 01/2021 - 06/2012
9	Stem Cell Transplantation 01/2022 - 10/2013
3	Transplantation 01/2020 - 02/2015
2	Aftercare (After-Treatment) 01/2021 - 09/2015
1	Treatment Delay 01/2022
1	Off-Label Use 01/2020
1	Drug Therapy (Chemotherapy) 01/2020
1	Injections 01/2020
1	Intramuscular Injections 09/2015